Clinical Trial Update: GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Epilepsy

Drugs mentioned

• cannabidiol (GWP42003-P) (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Epilepsy, Dravet Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2019-08-01